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EditorialCredibility and ReproducibilityCredibility is everything for science, and it is built over time in
both obvious and subtle ways. It is how we interact with col-
leagues and collaborators. It is how generously and openly we
share reagents and how we mentor students and postdocs. It
is how we review each other’s papers, and it is how we credit
others’ work. It is the way we educate and inform the public
that funds us. It is the way we document and store our data.
And it is the rigor, transparency, and attention we invest in
designing, conducting, and reporting experiments. Without
credibility, others can’t/won’t build on our work, and as a result,
the pace of scientific advance is slowed. Most importantly, sci-
ence contaminated with a lack of credibility is a housewith crum-
bling walls that engenders little trust and provides minimal value
to our global society, present and future.
But everyone reading this already knows the importance of
credibility in science, so why are we discussing it here? Within
the last 12 months the reproducibility of science, a lynchpin of
credibility, has come under intense scrutiny, both from the NIH
(Nature 505, 612–613) and other government funding bodies,
as well as in the lay (The Economist, October 19, 2013, 23–28)
and scientific press (Nature 483, 531–533—though many of
these reports themselves would benefit from greater transpar-
ency in reporting and still require robust demonstrations of
reproducibility). Hearing the word ‘‘reproducibility,’’ most of us
think immediately of fraud or data and image manipulation, but
it is much broader than that. Many of the current concerns about
reproducibility, particularly the successful scalability of preclini-
cal data into robust drug targets for treating human disease, are
focused on the rigor of the experimental design (inclusion of all
appropriate controls, blinded experimental conditions, gender
balance in experimental populations, a priori determination of
n’s and statistical power, appropriate statistical analyses, etc.)
and on complete transparency in reporting of these parameters
and all collected data (for a recent Perspective on this topic, see
Neuron 84, 572–581.)
In June of this year Francis Collins, NIH Director, Marcia
McNutt, Editor-in-Chief of Science, and Philip Campbell, Edi-
tor-in-Chief of Nature, organized a meeting of journal editors
and other contributors to collaborate on approaches to
ensuring and improving reproducibility. Maximizing reproduc-
ibility clearly is an initiative involving many stakeholders, with
scientists front and center and funding bodies, universities,
journals, pharmaceutical and biotech companies, patient
advocacy groups, and society at large all taking a leading
role as well. Out of the discussions at this meeting came a
set of recommendations for how journals and journal editors
can do their part. The main focus of the guidelines is to
ensure rigorous experimental design and transparency in re-
porting the specifics about how experiments were performed
and how data were collected and analyzed. Cell Press partici-
pated in the meeting and is a signatory on the recommenda-
tions that were recently posted (http://www.nih.gov/about/
reporting-preclinical-research.htm). Many of the items in the
guidelines Cell and its sister journals are already doing andRehave been doing for quite some time (providing space for
lengthy methods sections in print and unlimited supplemental
methods online, requiring the sharing of reagents as a condition
of publication, providing a forum for refutation in our Matters
Arising format, requiring authors to clearly state their statistical
measures.) Other items in the guidelines, like developing a way
to facilitate clear reporting in the paper of details about how
experiments were designed and performed, will be valuable
additions to what we already do. Journals are encouraged to
adopt a checklist of specific reporting criteria as a standard
form for authors to complete and editors and/or reviewers to
verify. While we at Cell and the other Cell Press journals are
not yet sure that an author checklist per se will be the
most effective implementation for our authors, reviewers, and
readers, we do wholly embrace the importance of the goals
of the guidelines and will be taking steps to adapt our editorial
processes and author instructions to ensure consistent stan-
dards for appropriate experimental design and transparency
in reporting. For example, Developmental Cell has recently
introduced supplemental protocols, where authors of a paper
with noteworthy, new, or particularly challenging methods are
encouraged to provide a detailed protocol in a separate sup-
plemental PDF. We view these steps as an important part of
the value that we add through the editorial and peer review
process.
Enhanced attention to these elements will also help protect
the authors’ credibility. With increased clarity about how exper-
iments were performed and collected, editors, authors, and re-
viewers will all be better able to spot and rectify concerns before
the paper is published, hopefully reducing the number of cor-
rections and retractions required postpublication. To this end,
Cell and our sister journals are also introducing an image
screening process to help ensure adherence to community
standards as outlined in our data processing policies. More
and more, we are finding that the concerns that arise regarding
published data are often the result of avoidable errors. For
example, copying and pasting the same image into two different
figures or failing to indicate where lanes of a gel have been
spliced together. (Oddly, the most pervasive challenges to pub-
lished data we see at Cell relate to loading controls. There
seems to be some misalignment among scientists regarding
the importance and meaning of the actin bands in a standard
western blot.) When potential problems are brought to our
attention by a concerned reader, we ask the authors to provide
us with the original unprocessed data, together with a detailed
explanation of how they conducted the experiment. Most of
the time, we can see from the raw data that the problems
have been introduced through simple mistakes and can be ad-
dressed with an erratum. But a scientific literature peppered
with corrections does not build credibility, and worse still is
when the avoidable errors are sufficiently extensive that they
undermine the reliability of the entire body of work and necessi-
tate a retraction. So, as we at Cell invest in checking figures and
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Editorialpaper is published, we ask that authors renew their focus on
preparing their manuscripts and reviewing the final figures
with the same attentive eyes their readers will. By combining
enhanced clarity of reporting as recommended by the new
guidelines with prepublication image screening, our intent is to
ensure that every paper we publish meets not only the highest
standards of interest and importance but also of credibility
and reproducibility.772 Reprinted from Cell 159, November 20, 2014 ª2014 Elsevier IncWith increased vigilance from authors, funders, and journals
and attention to standards for experimental design and accu-
rate careful reporting, we will collectively increase the public
trust and support for research and build a stronger pipeline
for converting our understanding of the basic processes
and mechanisms of biology into improved diagnostics, treat-
ments, and potentially cures for the myriad of global health
challenges.Emilie Marcus
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